|| Checking for direct PDF access through Ovid
The oral immunomodulator teriflunomide (Aubagio®) is approved in the EU for the treatment of adults with relapsing–remitting multiple sclerosis (RRMS). In phase III trials, teriflunomide was more effective than placebo in the prevention of relapses in this patient population, and there was no significant difference between teriflunomide and interferon-β-1a in the annualized relapse rate. Relative to placebo, teriflunomide also consistently reduced the risk of sustained disability progression and was associated with better magnetic resonance imaging outcomes. Oral teriflunomide was generally well tolerated in patients with RRMS, although it was associated with elevated ALT levels and has a potential risk for teratogenicity, based on animal studies.